Faecal microbiota transplantation: an emerging solution for recurrent infections
DOI:
https://doi.org/10.56294/shp2024122Keywords:
Clostridioides, Microbiota, Recurrence, Antibiotics, Latin AmericaAbstract
Clostridioides difficile infection was one of the main causes of antibiotic-associated diarrhoea, especially in Latin America, where its incidence increased considerably. Traditionally, it was treated with antibiotics such as metronidazole and vancomycin, although fidaxomicin emerged as a more effective option. However, the high recurrence rates prompted exploration of faecal microbiota transplantation (FMT), which proved more effective in recurrent cases. Although FMT was recognised as a promising therapy, its implementation in Latin America faced barriers such as a lack of protocols, infrastructure, regulation and cultural acceptance. Despite these challenges, scientific evidence supported its progressive incorporation into health systems.
References
1. Martínez JV, Raush A, Efrón ED, Zubiaurre I, Pinoni MV, Giorgio PL, et al. Colitis refractaria por Clostridium difficile tratada con trasplante de microbiota fecal [Refractory colitis by Clostridium difficile treated with fecal microbiota transplant]. Medicina (B Aires). 2019;79(4):291–4. Spanish. PMID: 31487251.
2. Xu Q, Zhang S, Quan J, Wu Z, Gu S, Chen Y, et al. The evaluation of fecal microbiota transplantation vs vancomycin in a Clostridioides difficile infection model. Appl Microbiol Biotechnol. 2022 Oct;106(19-20):6689–700. doi: 10.1007/s00253-022-12154-z. Epub 2022 Sep 10. PMID: 36085529.
3. Gupta K, Tappiti M, Nazir AM, Koganti B, Memon MS, Aslam Zahid MB, et al. Fecal Microbiota Transplant in Recurrent Clostridium difficile Infections: A Systematic Review. Cureus. 2022 May 5;14(5):e24754. doi: 10.7759/cureus.24754. PMID: 35693372; PMCID: PMC9174020.
4. Tixier EN, Verheyen E, Ungaro RC, Grinspan AM. Faecal microbiota transplant decreases mortality in severe and fulminant Clostridioides difficile infection in critically ill patients. Aliment Pharmacol Ther. 2019 Nov;50(10):1094–9. doi: 10.1111/apt.15526. Epub 2019 Oct 14. PMID: 31612528; PMCID: PMC6817391.
5. Health Quality Ontario. Fecal Microbiota Therapy for Clostridium difficile Infection: A Health Technology Assessment. Ont Health Technol Assess Ser. 2016 Jul 1;16(17):1–69. PMID: 27516814; PMCID: PMC4973962.
6. Minkoff NZ, Aslam S, Medina M, Tanner-Smith EE, Zackular JP, Acra S, et al. Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile). Cochrane Database Syst Rev. 2023 Apr 25;4(4):CD013871. doi: 10.1002/14651858.CD013871.pub2. PMID: 37096495; PMCID: PMC10125800.
7. Wilcox MH, McGovern BH, Hecht GA. The Efficacy and Safety of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection: Current Understanding and Gap Analysis. Open Forum Infect Dis. 2020 Apr 11;7(5):ofaa114. doi: 10.1093/ofid/ofaa114. PMID: 32405509; PMCID: PMC7184446.
8. Dinleyici M, Vandenplas Y. Clostridium difficile Colitis Prevention and Treatment. Adv Exp Med Biol. 2019;1125:139–46. doi: 10.1007/5584_2018_322. PMID: 30689174.
9. Song JH, Kim YS. Recurrent Clostridium difficile Infection: Risk Factors, Treatment, and Prevention. Gut Liver. 2019 Jan 15;13(1):16–24. doi: 10.5009/gnl18071. PMID: 30400734; PMCID: PMC6346998.
10. Cheng YW, Fischer M. Fecal Microbiota Transplantation: Redefining Surgical Management of Refractory Clostridium difficile Infection. Clin Colon Rectal Surg. 2020 Mar;33(2):92–7. doi: 10.1055/s-0040-1701233. Epub 2020 Feb 25. PMID: 32104162; PMCID: PMC7042019.
Published
Issue
Section
License
Copyright (c) 2024 Juliana Stupnik , Gerardo Laube (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
